Chimerix (NASDAQ:CMRX)

CAPS Rating: 2 out of 5

Results 1 - 5 of 5

Recs

0
Member Avatar Sparticus501 (< 20) Submitted: 10/10/2014 9:31:29 PM : Outperform Start Price: $32.71 CMRX Score: -2.02

Leading in the fight with Ebola.

Recs

0
Member Avatar 3barns (< 20) Submitted: 10/3/2014 10:07:15 AM : Underperform Start Price: $30.46 CMRX Score: -9.13

CFO selling his stock

Recs

3
Member Avatar zzlangerhans (99.85) Submitted: 9/9/2014 6:49:52 PM : Underperform Start Price: $27.23 CMRX Score: -24.65

Chimerix is ripping of late and I smell a rat. The stock was ailing in May even after the company solved their compassionate use PR nightmare, and management found the exact bottom of the stock to price a huge dilutive financing of 112M. Since then the stock has more than doubled, but why? The SUPPRESS phase III trial of brincidofovir for CMV prophylaxis is enrolling but topline data was subtly pushed back from mid 2015 to H2 2015. Don't expect it before the very end of 2015 if another delay isn't announced. Enrollment also continues in the pilot portion of the AdVise phase III trial of brincidofovir for adenoviral infections. Remember that this is the trial Chimerix never wanted to run, but were forced into because of the public outcry in response to their refusal to provide brincidofovir to a child dying of adenoviral infection.

Lately, the Chimerix PR department has gone into overdrive with reports of in vitro activity of brincidofovir against Ebola virus and favorable resistance profiles for brincidofovir against adenovirus and CMV. These efforts have clearly contributed to the run in Chimerix stock, but why does the company feel the need to promote themselves now after selling 8 million shares at the low? That's not how it's supposed to work in developmental biotech. Pump first, then finance. Where were these guys when they had the free seminar? So perhaps there's another financing coming, but the balance sheet certainly isn't screaming for it.

Chimerix's market cap was over a billion at the close today. That's a lot of coin for a company developing drugs for indications with uncertain commercial potential. CMV and adenovirus are not hepatitis. And Ebola? Give me a break. We've already been through this with Tekmira, Biocryst, and Sarepta. It's for momentum traders only. Now that I've had a little taste of success with shorting, Chimerix's rapid rise on dubious PR and sellside upgrades is quickly moving it to the top of my wishlist for a borrow.

Recs

0
Member Avatar docwahala (< 20) Submitted: 3/11/2014 1:35:45 AM : Outperform Start Price: $19.74 CMRX Score: +67.12

Anyone tracking the story about Chimerix in the news? Negative publicity about denying a 7-yr old medicine.

Recs

0
Member Avatar TerryHoodSr (59.59) Submitted: 12/30/2013 8:22:03 AM : Outperform Start Price: $15.04 CMRX Score: +119.79

TP $29

Results 1 - 5 of 5

Featured Broker Partners


Advertisement